TITLE

No Working Kinase, but ErbB3 Acquires Oncogenic Mutations

AUTHOR(S)
Breindl, Anette
PUB. DATE
May 2013
SOURCE
BioWorld Today;5/15/2013, Vol. 24 Issue 93, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the avian erythroblastosis oncogene B (ErbB) family of receptor tyrosine kinases. It informs that epidermal growth factor receptor (EGRF), the better-known alias of ErbB1, is the target of drugs such as Tarceva, Iressa,Vectibix and Erbitux. The article also mentions that researchers have presented evidence that ErbB3, at third ErbB family member, can also acquire activating for oncogenic mutations.
ACCESSION #
87646726

 

Related Articles

  • MiRNA-125a-5p: a regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma. Yanyang Liu; Zhixi Li; Lu Wu; Zi Wang; Xia Wang; Yang Yu; Qian Zhao; Feng Luo // Cancer Cell International;2014, Vol. 14 Issue 1, p1 

    Background Nasopharyngeal carcinoma (NPC) is a common malignancy in China and Southeast Asia. Radiotherapy is the major treatment modality for patients with NPC, but does not always achieve fully satisfactory outcomes. Studies have shown that epidermal growth factor receptor (EGFR) is highly...

  • Adenosquamous cell lung cancer successfully treated with gefitinib: A case report. KOICHI KURISHIMA; GEN OHARA; KATSUNORI KAGOHASHI; HIROKO WATANABE; NORIO TAKAYASHIKI; ATSUSHI ISHIBASHI; HIROAKI SATOH // Molecular & Clinical Oncology;2014, Vol. 2 Issue 3, p282 

    Although adenosquamous cell lung cancer (ASCLC) is included in the non-small-cell lung cancers (NSCLCs), the number of currently available studies on the response of this type of cancer to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is limited. This is the case report...

  • Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Melosky, Barbara // Frontiers in Oncology;Sep2014, Vol. 4, p1 

    Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic non-small cell lung cancer. Most of these recent trials were conducted in patients with EGFR mutation-positive...

  • Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. Ying Yuan; Xiao-Fen Li; Jia-Qi Chen; Cai-Xia Dong; Shan-Shan Weng; Jian-Jin Huang // OncoTargets & Therapy;2014, Vol. 7, p841 

    Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors can significantly improve clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and sensitive EGFR gene mutations. Gefitinib (Iressa®), the...

  • The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs. Yuli Wang; Hongyu Liu; Jun Chen // Chinese Journal of Lung Cancer;Apr2010, Vol. 13 Issue 4, p375 

    Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), gefitinib (Iressa) and erlotinib (Tarceva), are two prospective agents towards non-small cell lung cancer (NSCLC). Multi-center clinical...

  • Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Otto, Claudia; Csanadi, Agnes; Fisch, Paul; Werner, Martin; Kayser, Gian // Diagnostic Pathology;2012, Vol. 7 Issue 1, p146 

    Lung cancer is the leading cause of death among malignant diseases in humans worldwide. In the last decade development of new targeted drugs for the treatment of non-small cell lung cancer proved to be a promising approach to prolong the otherwise very poor prognosis of patients with advanced...

  • Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance. Xiang-Nan Li; Dong Qiu; Xue Pan; Xiao-Xu Hou // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 4, p5397 

    Mutations in the epidermal growth factor receptor (EGFR) gene are associated with subsets of non-small cell lung cancer (NSCLC). Some patients with EGFR mutations are responsive to targeted therapy with the EGFR tyrosine kinase inhibitor gefitinib. Here, the mutation status of EGFR was assessed...

  • An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. Ying Zhang; Huaping Tang; Jun Li; Meng Li // OncoTargets & Therapy;2015, Vol. 8, p1351 

    Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%-75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the...

  • Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. FERRAZZI, ANNA; RUSSO, IRENE; PASELLO, GIULIA; ALAIBAC, MAURO // Experimental & Therapeutic Medicine;Jan2016, Vol. 11 Issue 1, p197 

    Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne-like eruption. Cutaneous...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics